Loading...
•
Sep 30, 2021
Co-Diagnostics Q3 2021 Earnings Report
Reported continued strength with record revenue of $30.1 million, pre-tax income of $13.6 million, and fully diluted EPS of $0.38.
Key Takeaways
Co-Diagnostics reported strong Q3 2021 financial results, achieving record revenue of $30.1 million and a fully diluted EPS of $0.38. The company is optimistic about its upcoming point of care/at-home diagnostic platform and its potential impact on infectious disease diagnostics.
Achieved record revenue of $30.1 million in Q3 2021.
Reported pre-tax income of $13.6 million.
Fully diluted EPS reached $0.38.
Received ANVISA approval to sell Logix Smart COVID-19 test kit in Brazil.
Forward Guidance
Co-Diagnostics is offering the following guidance for its full year of 2021
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...